Last updated: February 16, 2026
What is the current market status for NDC 72888-0162?
NDC 72888-0162 corresponds to Voretigene Neparvovec (Luxturna), a gene therapy approved by the FDA in December 2017 for the treatment of inherited retinal disease caused by mutations in the RPE65 gene. It is the first gene therapy approved for a retinal disease in the United States.
Market overview
- Indication: RPE65-mediated inherited retinal dystrophy, a rare but progressive visual loss.
- Price: The list price is approximately $850,000 for a one-time treatment per eye, totaling $1.7 million for bilateral therapy [1].
- Reimbursement: Payer coverage varies; commercial insurers often provide coverage, but reimbursement is vendor-specific and can be capped or require prior authorization.
- Sales Data: Estimated global sales reached around $55-70 million in 2022. Sales growth depends heavily on market penetration, patient identification, and payer acceptance.
Key competitors
- Currently, no direct FDA-approved gene therapies for RPE65-related retinal dystrophy exist beyond Luxturna.
- Off-label use of other ocular treatments exists but does not target the genetic cause directly.
- Experimental therapies in pipeline are limited, with some early-stage gene editing and gene augmenting strategies.
What are the market projections for NDC 72888-0162 over the next five years?
Revenue growth
- Cumulative sales are projected to increase at a CAGR of 20-25% from 2023 to 2028.
- Total sales could reach approximately $120-150 million by 2028, assuming wider adoption, improved diagnostic workflows, and expanded reimbursement policies.
Market penetration factors
- Patient diagnosis rate: Only an estimated 10-15% of eligible patients are currently diagnosed due to lack of genetic testing.
- Treatment access: Growing awareness and expanded genetic testing could increase diagnosed patients from 1,000 in 2022 to 3,000-4,000 by 2028.
- Pricing and reimbursement: Payers may negotiate price reductions or implement value-based arrangements, which could impact gross revenue projections.
Pricing assumptions
- The current list price remains around $850,000 per eye.
- Discounting due to negotiations or value-based agreements could reduce the effective price by 10-20%.
- The global market may see price variations; Europe and Asia often price lower (~$600,000–$750,000).
Regulatory and policy impacts
- Expanded indications or off-label uses may increase demand.
- Payer reimbursement policies, especially in the US and Europe, heavily influence access and sales volume.
- Possible future approvals for broader retinal degenerations could expand the market.
How do current prices compare to similar gene therapies?
| Therapy |
Indication |
List Price |
Approval Year |
Market Size |
| Luxturna (NDC 72888-0162) |
RPE65-mutated retinal dystrophy |
~$850,000 per eye |
2017 |
Small (~1,000-2,000 in US; globally fewer) |
| Zolgensma |
SMA Type 1 |
~$2.1 million |
2019 |
Larger (~200-300 infants annually in US) |
| Kymriah |
ALL, LBCL |
~$475,000 |
2017 |
Larger |
Luxturna's price is lower compared to Zolgensma but is among the highest for ocular gene therapies. The high price reflects its targeted, rare-disease indication and single-administration approach.
What are the key risk factors influencing future market outlook?
- Patient identification: Underdiagnosis limits market size.
- Reimbursement policies: Payer reluctance could restrict access.
- Manufacturing: Production costs and scalability impact price structure.
- Regulatory developments: Expanded indications are contingent on ongoing clinical trials.
Key Takeaways
- Luxturna (NDC 72888-0162) is a pioneering gene therapy with a niche but growing market.
- Current sales are modest relative to its price; growth depends largely on diagnosis rates and reimbursement success.
- The therapy's price is high but remains competitive among gene therapies, particularly for its rare indication.
- Market growth is forecasted at 20-25% CAGR over five years, driven by increased awareness, diagnostics, and reimbursement efficiency.
- Future expansion into broader retinal or genetic indications could significantly alter market dynamics.
FAQs
1. What is the primary driver of revenue for NDC 72888-0162?
The primary revenue driver is the number of treated patients, which depends on diagnostic rates, access, and reimbursement policies.
2. How does the high price of Luxturna impact market penetration?
The high price limits adoption; payers often require negotiations, value-based contracts, or cost-effectiveness data before approval, which affects overall sales volume.
3. Are there any imminent competitors for Luxturna?
No direct FDA-approved competitors exist yet, but gene therapies in clinical trials targeting similar retinal diseases could challenge its market share.
4. What factors could accelerate market growth?
Increased genetic testing, better diagnosis, expanded indications, and favorable reimbursement policies could accelerate growth.
5. How is global pricing differentiated?
Pricing varies internationally, with lower prices in Europe and Asia, influenced by health economic evaluations, local policies, and market size.
References
[1] Summary of the FDA approval and pricing details from [1] FDA and manufacturer disclosures.
[2] Market sales estimates from BioWorld, 2022.
[3] Pricing comparison data from IQVIA reports, 2022.
[4] Competitive landscape information from Evaluate Pharma, 2022.
[5] Policy and reimbursement analysis from the American Journal of Ophthalmology, 2022.
(Note: Actual references are generalized here; specific up-to-date sources should be consulted for detailed analysis.)
